Daiichi Sankyo, Eli Lilly TRILOGY ACS Study Fails To Meet Primary Endpoint

Daiichi Sankyo Company and Eli Lilly announced that the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) study has failed to meet the primary endpoint.
Pharmaceutical Business Review